Related Experiment Video

Updated: Feb 10, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.3K

Targeting the Sarcomere: Myosin Inhibitors as the Revolutionary Game Changer in Hypertrophic Cardiomyopathy

Farbod Sedaghat-Hamedani1,2,3, Elham Kayvanpour1,2,3, Benjamin Meder1,2,3

  • 1Department of Cardiology, Angiology and Pneumology, Institut für Cardiomyopathien Heidelberg, University of Heidelberg, 69120 Heidelberg, Germany.

Reviews in Cardiovascular Medicine
|February 9, 2026
PubMed

Insights

Hypertrophic cardiomyopathy (HCM) is a common inherited heart disease. Cardiac myosin inhibitors (CMIs) offer a new, disease-specific treatment by targeting hypercontractility, improving patient outcomes.

Area of Science:

  • Cardiology
  • Genetics
  • Pharmacology

Background:

  • Hypertrophic cardiomyopathy (HCM) is the most prevalent inherited cardiac condition.
  • It is a primary cause of heart failure, arrhythmias, and sudden cardiac death in young people.
  • Current management focuses on symptom relief and invasive procedures for advanced cases.

Purpose of the Study:

  • To review the mechanistic basis of sarcomere modulation in HCM.
  • To summarize clinical evidence for cardiac myosin inhibitors (CMIs) like mavacamten and aficamten.
  • To critically evaluate the role of CMIs in both obstructive and non-obstructive HCM.

Main Methods:

  • Review of scientific literature on HCM pathogenesis and treatment.
  • Analysis of clinical trial data for CMIs.
  • Evaluation of molecular mechanisms of sarcomere function.

Main Results:

  • Identification of pathogenic sarcomere variants and hypercontractility as key disease drivers.
  • CMIs represent the first disease-specific pharmacological therapy for HCM.
  • Clinical evidence supports the efficacy of mavacamten and aficamten.

Conclusions:

  • CMIs offer a revolutionary therapeutic approach for HCM.
  • These drugs translate molecular discoveries into effective clinical applications.
  • CMIs are redefining the standard of care for HCM patients.

Keywords:
aficamtenhypertrophic cardiomyopathymavacamtenmyosin heavy chainsmyosin inhibitorsprecision medicine

More Related Videos

Sarcomere Shortening of Pluripotent Stem Cell-Derived Cardiomyocytes using Fluorescent-Tagged Sarcomere Proteins.08:37

Sarcomere Shortening of Pluripotent Stem Cell-Derived Cardiomyocytes using Fluorescent-Tagged Sarcomere Proteins.

Published on: March 3, 2021

4.9K
A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring05:54

A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring

Published on: November 29, 2024

2.2K

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
509
The Sarcomere01:08

The Sarcomere

A sarcomere is a microscopic segment repeating in a myofibril. The sarcomere fundamentally consists of two main myofilaments: thick filaments called myosin and thin filaments called actin. These filaments interact by sliding past each other in response to stimulus. In addition to myosin and actin, several other proteins, such as tropomyosin, troponin, titin, nebulin, myomesin, α-actinin, and dystrophin, play crucial roles in regulating, structuring, and functioning of the sarcomere.
Each...
16.4K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
588
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
580
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
465